Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Voth AR"'
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
Publikováno v:
OncoTargets and Therapy, Vol Volume 15, Pp 165-180 (2022)
Geraldine O’Sullivan Coyne,1 Chris Karlovich,2 Deborah Wilsker,3 Andrea Regier Voth,3 Ralph E Parchment,3 Alice P Chen,1 James H Doroshow4 1Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Insti
Externí odkaz:
https://doaj.org/article/3be61c77e444446294bde147fd416feb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mittra A; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA.; Division of Medical Oncology, The Ohio State University, Columbus, OH, 43210, USA., Coyne GHOS; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA., Zlott J; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA., Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA.; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA., Meehan R; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA., Rubinstein L; Biometric Research Program, National Cancer Institute, Bethesda, MD, 20892, USA., Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Wilsker D; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Ji J; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Miller B; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Navas T; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, 10591, USA., Ferry-Galow KV; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Chang TC; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Jiwani S; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Parchment RE; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA.; Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD, 20892, USA. chenali@mail.nih.gov.
Publikováno v:
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2024 Mar; Vol. 93 (3), pp. 177-189. Date of Electronic Publication: 2023 Nov 27.
Autor:
O'Sullivan Coyne G; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Kummar S; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Hu J; University of Southern California, Los Angeles, California., Ganjoo K; Stanford Cancer Center, Stanford University, Palo Alto, California., Chow WA; City of Hope Medical Center, Duarte, California., Do KT; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Zlott J; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Bruns A; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Foster JC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Meehan R; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Piekarz R; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Takebe N; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Bottaro D; Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Costello R; Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Wright JJ; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Doroshow JH; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland. chenali@mail.nih.gov.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jan 15; Vol. 28 (2), pp. 279-288. Date of Electronic Publication: 2021 Oct 29.
Autor:
Kummar S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA.; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA., Srivastava AK; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Navas T; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.; Pfizer Inc, Groton, CT, 06340, USA., Cecchi F; Urologic Oncology Branch, NCI, Bethesda, NIH, 20892, USA.; AstraZeneca, Inc, Gaithersburg, MD, 20878, USA., Lee YH; Urologic Oncology Branch, NCI, Bethesda, NIH, 20892, USA.; Altimmune, Inc, Gaithersburg, MD, 20878, USA., Bottaro DP; Urologic Oncology Branch, NCI, Bethesda, NIH, 20892, USA., Park SR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA.; Department of Oncology, University of Ulsan College of Medicine, Seoul, 138-736, South Korea., Do KT; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA.; Moderna Therapeutics, Inc, Cambridge, MA, 02139, USA., Jeong W; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA.; Millennium Physicians, Tomball, TX, 77375, USA., Johnson BC; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA., Voth AR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA., Rubinstein L; Biostatistics Branch, National Cancer Institute, Bethesda, MD, 20892, USA., Wright JJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA., Parchment RE; Clinical Pharmacodynamics Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA.; Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA. chenali@mail.nih.gov.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1577-1586. Date of Electronic Publication: 2021 Jun 28.
Autor:
Coyne GO; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kummar S; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Current address: Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA., Meehan RS; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Do K; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Collins JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Anderson L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Ishii K; Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Takebe N; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zlott J; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Piekarz R; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Lozier J; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hinoue T; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA., Laird PW; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA., Ferry-Galow KV; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, and Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Publikováno v:
Oncotarget [Oncotarget] 2020 Nov 03; Vol. 11 (44), pp. 3959-3971. Date of Electronic Publication: 2020 Nov 03 (Print Publication: 2020).
Autor:
Navas T; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Lawrence SM; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Ferry-Galow KV; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Borgel S; In Vivo Evaluation Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hollingshead MG; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Srivastava AK; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Alcoser SY; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Makhlouf HR; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Chuaqui R; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Wilsker DF; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Konaté MM; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Miller SB; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Voth AR; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Chen L; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Vilimas T; Molecular Characterization and Clinical Assay Development Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland., Subramanian J; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Rubinstein L; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Kummar S; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.; Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Chen AP; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.; Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Bottaro DP; Urologic Oncology Branch, NCI, NIH, Bethesda, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland.; Center for Cancer Research, NCI, NIH, Bethesda, Maryland., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland. parchmentr@mail.nih.gov.
Publikováno v:
Cancer research [Cancer Res] 2020 Jan 15; Vol. 80 (2), pp. 304-318. Date of Electronic Publication: 2019 Nov 15.
Autor:
Monks A; Molecular Pharmacology Group, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Zhao Y; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Hose C; Molecular Pharmacology Group, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Hamed H; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Krushkal J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Fang J; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Sonkin D; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Palmisano A; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Polley EC; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Fogli LK; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Konaté MM; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Miller SB; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Simpson MA; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Li MC; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Harris E; Molecular Pharmacology Group, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Wu X; Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Connelly JW; Molecular Pharmacology Group, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Rapisarda A; Molecular Pharmacology Group, Frederick National Laboratory for Cancer Research sponsored by the NCI, Frederick, Maryland., Teicher BA; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland., Simon R; Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, Maryland. doroshoj@mail.nih.gov.; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Publikováno v:
Cancer research [Cancer Res] 2018 Dec 15; Vol. 78 (24), pp. 6807-6817. Date of Electronic Publication: 2018 Oct 24.
Autor:
Hickman AB; Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Voth AR; Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Ewis H; Howard Hughes Medical Institute, Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Li X; Howard Hughes Medical Institute, Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Craig NL; Howard Hughes Medical Institute, Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA., Dyda F; Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Publikováno v:
Nucleic acids research [Nucleic Acids Res] 2018 Nov 02; Vol. 46 (19), pp. 10286-10301.
Autor:
Parchment RE; Clinical Pharmacodynamics Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD. Electronic address: parchmentr@mail.nih.gov., Voth AR; Clinical Pharmacodynamics Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD., Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Berzofsky JA; Vaccine Branch, National Cancer Institute, Bethesda, MD.
Publikováno v:
Seminars in oncology [Semin Oncol] 2016 Aug; Vol. 43 (4), pp. 501-13. Date of Electronic Publication: 2016 Jun 16.